Non-interventional study
A retrospective-prospective observational study to assess Landiolol utilization patterns in patients with supraventricular tachycardia, for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, for short-term control of the ventricular rate, or for non-compensatory sinus tachycardia (LANDI-UP)
Austria
Czechia
Germany
Greece
Hungary
Netherlands
Poland
Slovenia
EU PAS number:
EUPAS1000000297
First published:
03/12/2024
StudyFinalised
Nested case-control study evaluating effectiveness of immunization of girls and women of childbearing potential with GARDASIL(TM)/GARDASIL(TM) 9 against juvenile-onset recurrent respiratory papillomatosis (JoRRP) in Sweden, Denmark, and Norway (V503-095)
Denmark
Norway
Sweden
EU PAS number:
EUPAS1000000286
First published:
21/05/2025
StudyOngoing
Evaluating the Effectiveness of Eliquis® Additional Risk Minimization Measures in Kingdom of Saudi Arabia.
Saudi Arabia
EU PAS number:
EUPAS1000000270
First published:
21/05/2025
StudyPlanned
Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in Saudi Arabia
Saudi Arabia
EU PAS number:
EUPAS1000000266
First published:
28/11/2024
StudyOngoing
A long-term non-interventional study to assess the incidence of skin malignancies in patients with dystrophic and junctional epidermolysis bullosa receiving treatment with Filsuvez (FOSTER)
Austria
France
Germany
Greece
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000244
First published:
02/07/2025
StudyPlanned
LOOK-UP: Active pharmacovigilance study of the medicine Rinvoq™ (upadacitinib)
Portugal
EU PAS number:
EUPAS1000000227
First published:
04/07/2025
StudyFinalised
Shortening the time to confirm or to rebut Adverse events of interest related to innovative Therapies for immune-mediated inflammATory dIseases: cross-talking between different data sOURces. SATURATIOn study.
France
EU PAS number:
EUPAS1000000207
First published:
27/06/2024
StudyPlanned
A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with Severe Asthma Exposed to Tezepelumab (TREATY)
Denmark
France
Sweden
United States
EU PAS number:
EUPAS1000000176
First published:
04/07/2025
StudyPlanned
An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS)
Denmark
France
Germany
United States
EU PAS number:
EUPAS1000000169
First published:
04/07/2025
StudyPlanned
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design
Argentina
Australia
Belgium
Brazil
Canada
China
Colombia
Denmark
France
Greece
Israel
Italy
Japan
Korea, Republic of
Mexico
Netherlands
Norway
Portugal
Russian Federation
Spain
United States
EU PAS number:
EUPAS1000000149
First published:
10/03/2025
StudyOngoing